Multiple Sclerosis
Conditions
Brief summary
This study will identify a combination of disease severity markers (genetic, immunology, epigenetic, imaging) associated with disease severity and progression in a cohort of patients with multiple sclerosis.
Detailed description
The heterogeneity of multiple sclerosis evolution relies on several pathophysiological mechanisms including neuroinflammation, neurodegeneration and remyelination and repair mechanisms. The study will identify markers of disease severity in a longitudinal cohort of patients with multiple sclerosis who are siblings (both siblings having multiple sclerosis) including: biological markers (genetic, immunological and epigenetic markers, advanced MRI markers). An integrative model to predict disease progression will be proposed based on multimodal markers.
Interventions
OTHERComposite severity score calculation
Neurological examination, cognitive testing, and MRI exam
Sponsors
Institut National de la Santé Et de la Recherche Médicale, France
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Clinically isolated syndrome or Multiple sclerosis (2010 Mc Donald criteria) * Sibling having Clinically isolated syndrome or Multiple sclerosis (2010 Mc Donald criteria) willing to participate to the study * Affiliated to the French social security or equivalent
Exclusion criteria
* Cyclophosphamide, mitoxantrone or methylprednisolone infusion within one month before inclusion * Multiple sclerosis relapse within one month before inclusion * Concomitant severe or uncontrolled disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change of Expanded Disability Status Scale (EDSS) | Baseline and 18 months | Change in the Expanded Disability Status Scale (EDSS) which is the neurological assessment of disability related to multiple sclerosis. The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. Scoring is based on measures of impairment in eight functional systems on examination by a neurologist. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in neuropsychological scores | Baseline and 18 months | Change in the battery of neuropsychological tests adapted for multiple sclerosis |
| Change in T2 lesion volume | Baseline and 18 months | Change in volume of T2 lesion in the white matter |
| Grey matter volume change | Baseline and 18 months | Change in cerebral grey matter volume |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORCéline Louapre, MD, PhD
Institut du Cerveau et de la Moelle Epinière
Outcome results
None listed